Fig. 6: Anti-PD-L1 therapy blocks the tumor-promoting effects of PRMT3. | Cell Death & Disease

Fig. 6: Anti-PD-L1 therapy blocks the tumor-promoting effects of PRMT3.

From: PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma

Fig. 6

A PRMT3, p-PDHA, and PD-L1 were immunohistochemically analyzed using a tissue microarray (TMA) of HCC specimens (left). Scale bar, 50 μm. TMA analysis revealed a positive correlation between PRMT3 and p-PDHA expression, as well as with PD-L1 expression (right). B Timeline of the anti-PD-L1 therapy in Hepa1-6 cells of the subcutaneous mouse model. Hepa1-6 cells infected with Lenti-Prmt3 or Lenti-Ctrl were inoculated subcutaneously in the right flank of C57/BL/6 mice. Anti-PD-L1 was administered intraperitoneally on day 3 post-inoculation (twice per week, 100 μg/mouse). Tumor growth curve was shown. n = 7 in each group, *P < 0.05, **P < 0.01. Tumor images (C) and tumor weight (D) were shown. n = 7 in each group, *P < 0.05, **P < 0.01. E Semi-quantitative analysis of Ki67 and CD8 positive staining in the indicated tumor groups. n = 5 in each group, *P < 0.05, **P < 0.01. F Lactate production was detected in the indicated tumor groups. n = 5 in each group, *P < 0.05. G PD-L1 expression levels in the indicated tumor groups were analyzed by immunoblotting. The data are presented as mean ± SD, and the statistical tests were all two-tailed.

Back to article page